Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme
|Company Announcement |
Copenhagen, 21 Nov 2022
Transactions in connection with share buy-back programme
On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme.
Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023.
The following transactions have been executed from 14 November to 18 November 2022:
|Number of shares||Average |
purchase price, DKK
|Transaction value, DKK|
|Accumulated, last announcement||4,499,355||579,854,849|
|Total, 14 November – 18 November 2022||79,796||119.90||9,567,497|
|Bought from CAF, 18 November 2022*||35,612||119.90||4,269,859|
|Bought from CWO, 18 November 2022*||16,486||119.90||1,976,662|
|Accumulated under the programme||4,631,249||595,668,867|
*According to separate agreements as from 20 May 2022 Chr. Augustinus Fabrikker Aktieselskab (CAF) participates on a 27.0% pro-rata basis and C.W.Obel A/S (CWO) participates on a 12.5% pro-rata basis to the shares purchased in the share buy-back programme.
A detailed overview of transactions during the period 14 November – 18 November 2022 is attached to this announcement.
Following the above transactions Scandinavian Tobacco Group A/S owns a total of 5,077,311 treasury shares, corresponding to 5.46% of the total share capital.
For further information, please contact:
Torben Sand, Head of Investor Relations,
phone: +45 5084 7222 or email@example.com
- Company Announcement no 68 2022
- PDMR notification CAF 18 Nov 2022
- PDMR notification CWO 18 Nov 2022
- PUBLIC_SBB_SCANDINAVIAN TOBACCO GROUP
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
HYCU® Introduces World’s First Data Protection Development Platform for SaaS1.2.2023 14:30:00 CET | Press release
Now More Than 17,000 SaaS Vendors and ISVs Can Deliver Data Protection Services in Days, Enabling Their 59+ Billion Users to Backup and Recover in Minutes Boston, Massachusetts, Feb. 01, 2023 (GLOBE NEWSWIRE) -- HYCU, Inc., the world’s fastest-growing multi-cloud data protection as a service company, unveiled R-Cloud™ today, to allow Software as a Service (SaaS) companies and Independent Software Vendors (ISVs) to provide, in days, backup and recovery services for their SaaS offerings. R-Cloud is the world’s first low-code, purpose-built data protection development platform specifically designed to make it easy for SaaS vendors to deliver a true enterprise class backup and recovery service for their users that is secure and scalable. With more than 17,000 SaaS applications in use across organizations today, 99% of those applications have no reliable backup and recovery available. With the explosion of SaaS and the rapid modernization of applications, it is more difficult than ever t
Novo Nordisk files annual report with the SEC1.2.2023 14:20:49 CET | Press release
Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022 on Form 20-F for the financial year 2022 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2022. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders may receive a hardcopy of Novo Nordisk’s completed audited financial statements free of charge upon request to firstname.lastname@example.org. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information
RIKSBANK EXCHANGE OF EU PAYMENT1.2.2023 14:04:38 CET | Press release
Sweden's EU membership entails monthly contributions to the EU's budget. These payments are made in Swedish kronor by the Swedish government and exchanged into euro in the foreign exchange market by a recipient central bank within the EU. The Riksbank has decided to exchange an EU payment in February 2023. The total amount is SEK 3 347 million. The Riksbank has on previous occasions exchanged EU payments to avoid unnecessarily large fluctuations in the exchange rate in connection with these transactions. These exchanges do not have any monetary policy purpose. The effect on liquidity in the banking system is neutralised by means of FX-swaps. The Riksbank intends to repurchase the corresponding euro amount in the foreign exchange market within one month. For further information, please contact Front Office, Markets Department +46 8 696 6970
Sportradar Appoints Severine Riviere as Chief People Officer1.2.2023 14:00:36 CET | Press release
Company continues to scale its global leadership team to deliver accelerated growth ST. GALLEN, Switzerland, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sportradar (NASDAQ: SRAD) today announced the appointment of Severine Riviere as Chief People Officer, effective immediately. Riviere, who brings two decades of experience in global human resource management and business transformation to the role, will be responsible for all aspects of Sportradar's human resources strategy, including talent management, leadership development, total rewards, and workplace culture, and will report directly to Sportradar CEO Carsten Koerl. Riviere joins Sportradar from Fyffes International where she served as Chief Human Resources Officer and launched strategic plans to improve operational efficiency and transform culture. Throughout her career, Riviere has worked in human capital management for international, multi-industry B2B and B2C businesses ranging from 5,000 to 85,000 employees and developed a successful t
Merus to Participate in Upcoming Investor Conferences1.2.2023 14:00:00 CET | Press release
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences: Guggenheim Healthcare Talks/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ETSVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ETCiti's 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therap